Glaukos Corporation

GKOS Healthcare Medical Devices

Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.

Revenue
+58.0%
EPS
+110.7%
Free cash flow
+411.2%
Total debt
−2.25%

Quarter to September 2026, against a year earlier

224.36 4.38 +1.99%
Market cap
$13.0B
P/E
0.0×
Fwd P/E
−803×
Dividend yield
—
F-score
3/9
Altman Z
15.20
Beneish M
−2.96
Dividend safety
n/a

Glaukos Corporation (GKOS) P/E ratio

Alert me on P/E ratio

Glaukos Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 646× (October 2016) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 160× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 253× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
43 more quarters

Against its own ten years

Low 0.0× High 646×
Ten-year median 0.0×
Current reading's percentile 91

P/E ratio against peers

Company P/E ratio
BRKR Bruker Corporation compare n/m
GKOS Glaukos Corporation n/m
BIO Bio-Rad Laboratories, Inc. compare 9.7×
BIO.B Bio-Rad Laboratories, Inc. compare 9.9×
GMED Globus Medical, Inc. compare 19.5×
PODD Insulet Corporation compare 25.2×
ZBH Zimmer Biomet Holdings, Inc. compare 26.9×
SNN Smith & Nephew SNATS, Inc. compare 38.9×
PEN Penumbra, Inc. compare 80.3×
Medical Devices industry median 25.6×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on GKOS